Praxis Precision Medicine's Vormatrigine Shows Promising Mid-Stage Trial Results for Anti-Seizure Therapy

Praxis Precision Medicines (NASDAQ:PRAX) stock surged 18% in the premarket after announcing topline results from a mid-stage trial for vormatrigine, its experimental therapy for focal onset seizures. The data from the Phase 2 RADIANT study showed positive results for the treatment.

Praxis Precision Medicines (NASDAQ: PRAX) stock surged 18% in the premarket on Monday following the announcement of topline results from a mid-stage trial for vormatrigine, its experimental therapy for focal onset seizures. The data, presented from the Phase 2 RADIANT study, showed promising results for the treatment.

The RADIANT study evaluated the efficacy and safety of vormatrigine in patients with focal onset seizures. The study found that dosing with vormatrigine over 8 weeks led to a 56.3% median reduction in seizure frequency. Approximately 22% of patients achieved a 100% reduction in seizure frequency in the last 28 days on treatment, and over 54% of patients achieved a 50% response in the first week. Vormatrigine was generally well tolerated and demonstrated a favorable safety profile [2].

Marcio Souza, president and CEO of Praxis, expressed enthusiasm about the results. "We are thrilled by the best-in-disease topline results of this first cohort for the RADIANT study and for the potential to deliver a fast-acting, highly efficacious and tolerable therapy to patients living with focal epilepsy," he said. Souza noted that the findings build on earlier clinical data showing a differentiated profile for vormatrigine, and that the company is well on track to complete the pivotal, 12-week POWER1 study in Q4 and initiate the POWER2 study shortly [2].

Jacqueline French, MD, Professor at NYU Langone Health's Comprehensive Epilepsy Center, commented on the potential of vormatrigine. "While several sodium channel therapies are already used to treat focal onset seizures, there remains substantial room for improvement within this class. A next-generation sodium channel blocker has the potential to represent an important step forward in addressing that gap," she said [2].

Praxis will present additional data from the RADIANT study at the 36th International Epilepsy Congress on August 31, 2025, in Lisbon, Portugal, and submit a late-breaker abstract for the American Epilepsy Society Annual Meeting in December 2025 in Atlanta, Georgia [2].

References:
[1] https://seekingalpha.com/news/4477193-praxis-precision-stock-jumps-trial-data
[2] https://www.morningstar.com/news/globe-newswire/9505231/praxis-precision-medicines-announces-positive-best-in-disease-topline-results-in-patients-with-focal-onset-seizures-from-the-radiant-study-of-vormatrigine